<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        23-968-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EFRAM XR 750 mg TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Extended-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        137.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAMMAM PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1898]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EFRAM XR is a prescription medicine taken by mouth that is used with other medicines to treat partial onset seizures in people 16 years of age and older with epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known if EFRAM XR is safe or effective in people under 16 years of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before taking your medicine, make sure you have received the correct medicine. Compare the name above with the name on your bottle and the appearance of your medicine with the description of EFRAM XR provided below. Tell your pharmacist immediately if you think you have been given the wrong medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines are sometimes prescribed for purposes other than those listed in the leaflet. Do not use EFRAM XR for a condition for which it was not prescribed. Do not give EFRAM XR to other people, even if they have the same symptoms that you have. It may harm them.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This Leaflet summarizes the most important information about EFRAM XR. If you would like more information, talk with your doctor. You can ask your pharmacist or your doctor for information about EFRAM XR that is written for health professionals.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take EFRAM XR</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to levetiracetam or any of the other ingredients of this medicine (listed in Section 6).</p><p><strong>Take special care with EFRAM XR</strong></p><p>Before taking EFRAM XR, tell your doctor about all of your medical conditions, including if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have or have had depression, mood problems or suicidal thoughts or behavior.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have kidney problems.</p><p>Like other antiepileptic drugs, EFRAM XR may cause suicidal thoughts or actions in a very small number of people, about 1 in 500 people taking it.</p><p>Call your doctor right away if you have any of these symptoms, especially if they are new, worse, or worry you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts about suicide or dying.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attempts to commit suicide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worse depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worse anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling agitated or restless.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Panic attacks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trouble sleeping (insomnia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worse irritability.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acting aggressive, being angry, or violent.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acting on dangerous impulses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An extreme increase in activity and talking (mania).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other unusual changes in behavior or mood.</p><p>How can I watch for early symptoms of suicidal thoughts and actions?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all follow-up visits with your doctor as scheduled.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call your doctor between visits as needed, especially if you are worried about symptoms.</p><p><strong>Taking other medicines</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may result in a loss of its effect</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not start a new medicine without first talking with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Know the medicines you take. Keep a list of them to show your doctor and pharmacist each time you get a new medicine.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Taking EFRAM XR with food, drink and alcohol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take EFRAM XR with or without food. As a safety precaution, do not take EFRAM XR with alcohol.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Before taking EFRAM XR, tell your doctor about all of your medical conditions, including if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are pregnant or planning to become pregnant. It is not known if EFRAM XRwill harm your unborn baby. You and your doctor will have to decide if you should take EFRAM XR while you are pregnant. If you become pregnant while taking EFRAM XR, talk to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are breast feeding. EFRAM XR can pass into your milk and may harm your baby. You and your doctor should discuss whether you should take EFRAM XRor breast-feed; you should not do both.</p><p><strong>Driving and using machines</strong></p><p>Do not drive, operate machinery or do other dangerous activities until you know how EFRAM XR affects you. EFRAM XR may make you dizzy or sleepy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Take EFRAM XR exactly as prescribed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment should be initiated with a dose of 1000 mg once daily. The once daily dosage may be adjusted in increments of 1000 mg every 2 weeks to a maximum recommended once daily dose of 3000 mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you how much EFRAM XR to take and when to take it. EFRAM XR is usually taken once a day. Take EFRAM XR at the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may change your dose. Do not change your dose without talking to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets whole. Do not chew, break, or crush tablets.</p><p><strong>Method of administration</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow EFRAM XR tablets with a sufficient quantity of liquid (e.g. a glass of water).</p><p><strong>If you take more EFRAM XR than you should</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take too much EFRAM XR, go to the nearest emergency room right away.</p><p><strong>If you forget to take EFRAM XR</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of EFRAM XR, take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time.<strong>&nbsp;Do not take two doses at the same time.</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking EFRAM XR</strong></p><p>Do not stop EFRAM XR without first talking to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stopping EFRAM XR suddenly can cause serious problems. Stopping a seizure medicine suddenly can cause seizures that will not stop (status epilepticus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your doctor may check for other causes.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like other antiepileptic drugs, EFRAM XR may cause suicidal thoughts or actions in a very small number of people, about 1 in 500 people taking it.</p><p><strong>Call your doctor right away if you have any of these symptoms, especially if they are new, worse, or worry you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts about suicide or dying.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attempts to commit suicide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worse depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worse anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling agitated or restless.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Panic attacks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trouble sleeping (insomnia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worse irritability.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acting aggressive, being angry, or violent.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acting on dangerous impulses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An extreme increase in activity and talking (mania).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other unusual changes in behavior or mood.</p><p>EFRAM XR can cause serious side effects.</p><p>Call your doctor right away if you have any of these symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mood and behavior changes such as aggression, agitation, anger, anxiety, apathy, mood swings, depression, hostility, and irritability. A few people may get psychotic symptoms such as hallucinations (seeing or hearing things that are really not there), delusions (false or strange thoughts or beliefs) and unusual behavior.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme sleepiness, tiredness, and weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with muscle coordination (problems walking and moving).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A skin rash. Serious skin rashes can happen after you start taking EFRAM XR. There is no way to tell if a mild rash will become a serious reaction.</p><p>Common side effects seen in people who take EFRAM XR and other formulations of EFRAM XR include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>These side effects can happen at any time but happen more often within the first 4 weeks of treatment except for infection.</p><p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p><p>These are not all the possible side effects of EFRAM XR. For more information, ask your doctor or pharmacist.</p><p><strong>Call your doctor for medical advice about side effects.</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is levetiracetam.</p><p><u>For EFRAM XR500 mg:</u></p><p>Each film-coated tablet contains 500&nbsp;mg levetiracetam.</p><p>The other ingredients are:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Excipients: Avicel pH 101, Povidone 30, Purified Water, Hydroxypropylmethylcellulose K15M, Colloidal silicon dioxide, Purified Talc, Magnesium Stearate.</p><p>Coating composition: Hydroxypropyl methylcellulose, Titanium dioxide pharma grade, Polyethylene glycol MW6000, Purified Talc, Purified Water.</p><p><u>For EFRAM XR750 mg:</u></p><p>Each film-coated tablet contains 750&nbsp;mg levetiracetam.</p><p>The other ingredients are:</p><p>Excipients: Avicel pH 101, Povidone 30, Purified Water, Hydroxypropyl methylcellulose K15M, Colloidal silicon dioxide, Purified Talc, Magnesium Stearate.</p><p>Coating composition: Hydroxypropyl methylcellulose, Titanium dioxide pharma grade, Polyethylene glycol MW6000, Purified Talc, Purified Water.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                For EFRAM XR 500 mg:
EFRAM XR500 mg Film-Coated Tablets: White capsule shaped, biconvex, film-coated tablet, Engraved with T217 on one side and plain on other side.
Tablet containers: 30/pack.
Blisters: Reel OPA/AL/PVC blister and aluminum foil.

For EFRAM XR 750 mg:
EFRAM XR750 mg Film-Coated Tablets: White capsule shaped, biconvex, film-coated tablet, Engraved with T218 on one side and plain on other side.
Tablet containers: 30/pack.
Blisters: Reel OPA/AL/PVC blister and aluminum foil.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>DAMMAM PHARMA</p><p>Dammam pharmaceutical plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفرام م.م هو دواء وصفي يتم تناوله عن طريق الفم ويستخدم مع أدوية اخري في علاج البدايات الجزئية للنوبات لمن هم أعمارهم 16 عاما أو أكثر ولديهم صرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليس من المعروف اذا كان إيفرام م.م آمن أو فعال لمن هم أقل من 16 عاما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تناولك الدواء، عليك التأكد من انك قد حصلت علي الدواء الصحيح. قم بمقارنة اسم الدواء المذكر في الأعلي مع اسم الدواء الموجود علي عبوة الدواء وكذلك مواصفات الدواء مع المواصفات المذكورة في نهاية النشرة. قم باخبار الصيدلي مباشرة اذا اعتقدت انك قد حصلت علي دواء خاطئ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم وصف الأدوية احيانا في اغراض غير مذكورة بالنشرة. لا تقم بتناول إيفرام م.م في اي حالة لم يتم وصف هذا الدواء فيها. لا تقم باعطاء هذا الدواء للأخرين، حتي ولو كانوا يعانون من نفس الأعراض التي تعاني منها. لانه قد يضرهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذه النشرة تلخص معظم المعلومات الهامة عن إيفرام م.م. اذا اردت المزيد من المعلومات، قم بالتواصل مع طبيبك. يمكنك التواصل مع الصيدلي أو مع الطبيب للمزيد من المعلومات عن إيفرام م.م والتي تكون مكتوبة للمهنيين الصحيين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول إيفرام م.م</strong></p><p dir="RTL">إذا كنت تعاني من حساسية (فرط الحساسية) لـ ليفيتيراسيتام أو أي من المكونات الأخرى في هذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغى توخى الحذر مع إيفرام م.م</strong></p><p dir="RTL">قبل تناول إيفرام م.م، عليك التحدث مع طبيبك عن كل حالاتك الطبية، وذلك يتضمن اذا كنت:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك أو كان لديك اكتئاب، مشكلات في الحالة المزاجية أو أفكار أو سلوك انتحاري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في الكلي.</p><p dir="RTL">مثل باقي أدوية الصرع الأخري، قد يسبب إيفرام م.م أفكار أو أفعال انتحارية في عدد قليل جدا من الناس، حوالي 1 من كل 500 شخص يتناول هذا الدواء.</p><p dir="RTL">عليك التحدث الي طبيبك فورا اذا كان لديك اي من هذه الأعراض، وبخاصة اذا كانت جديدة أو أصبحت أكثر سوءا أو أصبحت تزعجك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار عن الانتحار أو الموت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاولات انتحار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة اكتئاب جديدة أو أصبحت أكثر سوءا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة قلق جديدة أو أصبحت أكثر سوءا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالهياج أو عدم الراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات ذعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم (الأرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة توتر جديدة أو أصبحت أكثر سوءا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بأعمال عدوانية، غاضبة أو عنيفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بنبضات خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مبالغ فيها في النشاط والتحدث (الهوس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات غير عادية أخري في السلوك أو المزاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيف يمكنك ملاحظة الأعراض المبكرة للأفكار أو الأفعال الانتحارية؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتبه لأية تغييرات، وخاصة التغيرات المفاجئة في المزاج، والسلوكيات، والأفكار، أو المشاعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حافظ على جميع زيارات المتابعة مع الطبيب كما كان مقررا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبك بين الزيارات حسب الحاجة، وخاصة إذا كنت قلقا بشأن الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخري</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم باخبار طبيبك بكل الأدوية التي تتناولها، وذلك يتضمن الأدوية الوصفية واللاوصفية، الفيتامينات، والمكملات العشبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تبدا بتناول دواء جديد دون اخبار طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ ماكروغول (دواء يستخدم كملين) لمدة ساعة واحدة قبل وساعة واحدة بعد أخذ ليفيتيراسيتام حيث أن هذا قد يؤدي إلى فقدان تأثيره</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليك معرفة كل الأدوية التي تتناولها. احتفظ بقائمة بهم وقم بتقديمها الي الطبيب أو الصيدلي في كل مرة تقم فيها بالحصول علي دواء جديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول إيفرام م.م مع الطعام والشراب والكحول </strong></p><p dir="RTL">تناول إيفرام م.م مع أو بدون الطعام. كإجراء احترازي، لا تتناول إيفرام مع الكحول.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">قبل تناول لفيتام م.م، قم بالتحدث مع طبيبك عن كل الحالات الطبية، وذلك يتضمن اذا كنت:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملا أو تخططين للحمل. ليس من المعروف اذا كان إيفرام م.م سوف يضر طفلك الذي لم يولد بعد. انت وطبيبك يجب عليكما ان تقررا اذا كان يجب عليك تناول إيفرام م.م أثناء الحمل. اذا اصبحت حاملا اثناء فترة علاجك ب إيفرام م.م ، عليك التحدث الي طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقومين بالرضاعة الطبيعية. يستطيع إيفرام م.م المرور الي اللبن وقد يضر الطفل. انت وطبيبك عليكما مناقشة اذا كان يجب عليكي تناول إيفرام م.م أو القيام بالرضاعة الطبيعية، لا يجب القيام بالأمرين في نفس الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقم بالقيادة، تشغيل الماكينات أو اداء اي انشطة خطرة حتي تعلم مدي تأثير إيفرام م.م عليك. إيفرام م.م قد يجعلك تشعر بالدوار أو النعاس.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;قم بتناول إيفرام م.م كما تم وصفه لك تماما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ان يبدأ العلاج بجرعة 1000 ملجم مرة واحدة يوميا. يمكن تعديل الجرعة الواحدة يوميا بزيادة 1000 ملجم كل اسبوعين الي ان تصل الي الجرعة القصوي وهي 3000 ملجم مرة واحدة يوميا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يقوم طبيبك باخبارك عن الكمية التي يجب ان تتناولها من إيفرام م.م وعن مواعيد تناولها. عادة يتم تناول إيفرام م.م مرة واحدة يوميا. قم بتناول إيفرام م.م في نفس الميعاد يوميا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم طبيبك بتغيير الجرعة الخاصة بك. لا تقم بتغيير الجرعة الخاصة بك دون التحدث الي طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم ببلع القرص بالكامل. لا تقم بمضغ، كسر أو سحق الأقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة التناول</strong></p><p dir="RTL">قم ببلع أقراص إيفرام م.م مع كمية كافية من السوائل (مثل كوب من الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اذا تناولت إيفرام م.م أكثر مما يجب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قمت بتناول الكثير من إيفرام م.م، انتقل إلى أقرب غرفة طوارئ على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اذا نسيت أن تتناول إيفرام م.م</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا نسيت ان تتناول جرعة من إيفرام م.م، تناولها في أقرب وقت ممكن بعد تذكرك. اذا تذكرت الجرعة ولكن في وقت قريب من ميعاد الجرعة التالية، تخطي هذه الجرعة. تناول الجرعة التالية في ميعادها المعتاد. لا تقم بتناول جرعتين في نفس التوقيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اذا توقفت عن تناول إيفرام م.م</strong></p><p dir="RTL">لا تقم بالتوقف عن تناول إيفرام م.م دون التحدث الي طبيبك أولا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوقف عن تناول إيفرام م.م بشكل مفاجئ قد يتسبب في مشاكل خطيرة. التوقف عن تناول علاج النوبات بشكل مفاجئ من الممكن ان يتسبب في حالات من النوبات التي لن تتوقف (حالة صرعية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأفكار أو الأفعال الانتحارية قد تنتج عن اشياء اخري غير الأدوية. اذا كانت لديك أي أفكار أو أفعال انتحارية، سوف يقوم طبيبك بفحص الأسبابا الأخري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل باقي الأدوية المضادة للصرع، قد يتسبب إيفرام م.م في بعض الأفكار أو الأفعال الانتحارية في فئة قليلة من الناس، حوالي 1 من كل 500 شخص ممن يتناولون هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك التحدث الي طبيبك فورا اذا كان لديك اي من هذه الأعراض، وبخاصة اذا كانت جديدة أو أصبحت أكثر سوءا أو أصبحت تزعجك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار عن الانتحار أو الموت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاولات انتحار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة اكتئاب جديدة أو أصبحت أكثر سوءا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة قلق جديدة أو أصبحت أكثر سوءا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالهياج أو عدم الراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات ذعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم (الأرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة توتر جديدة أو أصبحت أكثر سوءا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بأعمال عدوانية، غاضبة أو عنيفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بنبضات خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مبالغ فيها في النشاط والتحدث (الهوس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات غير عادية أخري في السلوك أو المزاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب إيفرام م.م في آثار جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بالاتصال بطبيبك فورا اذا كان لديك اي من هذه الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في السلوك والمزاج مثل العدوان، والإثارة، والغضب، والقلق، واللامبالاة، وتقلب المزاج، والاكتئاب، والعداء، والتهيج. عدد قليل من الناس قد تحصل أعراض ذهنية مثل الهلاوس (رؤية أو سماع الأشياء التي هي في الحقيقة ليست هناك)، والاوهام (أفكار أو معتقدات خاطئة أو غريبة) وسلوك غير عادي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس الشديد، والتعب، والضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل مع تنسيق العضلات (مشاكل المشي والتحرك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي. طفح جلدي خطير يمكن أن يحدث بعد البدء في تناول إيفرام م.م. لا توجد وسيلة لمعرفة ما إذا كان الطفح الخفيف سيصبح رد فعل خطير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية شائعة قد تظهر في الناس الذين يتناولون إيفرام م.م و التركيبات الأخري من إيفرام م.م تتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الأعراض قد تحدث في اي وقت ولكنها أكثر حدوثا خلال الاربع اسابيع الأولي من العلاج فيما عدا العدوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اخبر طبيبك اذا كان لديك اي من الأعراض الجانبية التي تضايقك أو التي تستمر دون ان تتوقف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه ليست كل الأعراض الجانبية المحتملة الحدوث من إيفرام م.م. للمزيد من المعلومات، عليك أن تسأل الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك للحصول علي النصيحة الطبية حول هذه الأعراض الجانبية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ الدواء بعيدا عن متناول ونظر الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد EXP. وتاريخ الإنتهاء يشير إلى أخر يوم فى الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يحفظ في درجة حرارة أكثر من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ليفيتيراسيتام</p><p dir="RTL"><u>إيفرام م.م 500 ملجم:</u></p><p dir="RTL">كل قرص مغلف يحتوي علي 500 ملجم ليفيتيراسيتام.</p><p dir="RTL">المكونات الأخري هي:</p><p dir="RTL">المواد المضافة: أفيسل درجة الحموضة 101، بوفيدون 30، ماء منقي، هيدروكسي بروبيل ميثيل سيليلوز K15M، ثاني اكسيد السيليكون الصمغي، تلك منقي، وماغنسيوم ستيرات.</p><p dir="RTL">تكوين التغليف: هيدروكسي بروبيل ميثيل سيليلوز، تيتانيوم ثنائي الأوكسيد درجة فارما، بولي ايثيلين جليكول MW6000، تلك منقي، و ماء منقي.</p><p dir="RTL"><u>إيفرام م.م 750 ملجم:</u></p><p dir="RTL">كل قرص مغلف يحتوي علي 750 ملجم ليفيتيراسيتام.</p><p dir="RTL">المكونات الأخري هي:</p><p dir="RTL">المواد المضافة: أفيسل درجة الحموضة 101، بوفيدون 30، ماء منقي، هيدروكسي بروبيل ميثيل سيليلوز K15M، ثاني اكسيد السيليكون الصمغي، تلك منقي، وماغنسيوم ستيرات.</p><p dir="RTL">تكوين التغليف: هيدروكسي بروبيل ميثيل سيليلوز، تيتانيوم ثنائي الأوكسيد درجة فارما، بولي ايثيلين جليكول MW6000، تلك منقي، و ماء منقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><u>إيفرام م.م 500 ملجم:</u></p><p dir="RTL" style="text-align:right">إيفرام م.م 500 ملجم أقراص مغلفة بطبقة رقيقة: كبسولة بيضاء الشكل، ثنائي التحدب، مغلفة بطبقة رقيقة، منقوش عليها T217 &nbsp;من جانب و جلية السطح على الجانب الأخر.</p><p dir="RTL" style="text-align:right">عبوات الأقراص: 30 في كل علبة.</p><p dir="RTL" style="text-align:right">حاويات الأقراص: حاوية من النوع OPA/ AL /PVC ورقاقة معدنية من الالومنيوم.</p><p dir="RTL" style="text-align:right"><u>إيفرام م.م 750 ملجم:</u></p><p dir="RTL" style="text-align:right">إيفرام م.م 750 ملجم أقراص مغلفة بطبقة رقيقة: كبسولة بيضاء الشكل، ثنائي التحدب، مغلفة بطبقة رقيقة، منقوش عليها T218&nbsp; من جانب و جلية السطح على الجانب الأخر.</p><p dir="RTL" style="text-align:right">عبوات الأقراص: 30 في كل علبة.</p><p dir="RTL" style="text-align:right">حاويات الأقراص: حاوية من النوع OPA / AL /PVC ورقاقة معدنية من الالومنيوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الدمام فارما</p><p dir="RTL">مصنع الأدوية بالدمام</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EFRAM XR 500, 750 & 1000 mg XR film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Efram XR (500mg): Each extended release film-coated tablet contains 500 mg levetiracetam.
For Efram XR (750mg): Each extended release film-coated tablet contains 750 mg levetiracetam.

For the full list of excipients, see section 6.1
Extended release film-coated tablet.
EFRAM XR500 mg Film-Coated Tablets: White capsule shaped, biconvex, film-coated tablet, Engraved with T217 on one side and plain on other side.

EFRAM XR750 mg Film-Coated Tablets: White capsule shaped, biconvex, film-coated tablet, Engraved with T218 on one side and plain on other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EFRAM XR is an antiepileptic drug available as 500 mg and 750 mg extended-release tablets for oral administration.
The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Efram XR is indicated as adjunctive therapy in the treatment of partial onset seizures in patients&rsquo; &ge;16 years of age with epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Efram XR is administered once daily.</p><p>&nbsp;</p><p>Treatment should be initiated with a dose of 1000 mg once daily. The once daily dosage may be adjusted in increments of 1000 mg every 2 weeks to a maximum recommended once daily dose of 3000 mg.</p><p>&nbsp;</p><p><strong><u>Special populations</u></strong></p><p><em><u>Adult Patients with Impaired Renal Function</u></em></p><p><em>&nbsp;</em></p><p>Efram XR dosing must be individualized according to the patient&#39;s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this, an estimate of the patient&#39;s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:</p><table border="0" cellspacing="0" cellpadding="0" style="width:50%"><tbody><tr><td rowspan="2"><p>CLcr=</p></td><td><p>[140-age (years)] &times; weight (kg)</p></td><td rowspan="2"><p>(&times; 0.85 for female patients)</p></td></tr><tr><td><p>72 &times; serum creatinine (mg/dL)</p></td></tr></tbody></table><p>Then CLcr is adjusted for body surface area (BSA) as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:50%"><tbody><tr><td rowspan="2"><p>CLcr (mL/min/1.73m2)=</p></td><td><p>CLcr (mL/min)</p></td><td rowspan="2"><p>&times; 1.73</p></td></tr><tr><td><p>BSA subject (m2)</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:75%"><thead><tr><td colspan="4"><p>Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function</p></td></tr><tr><td style="vertical-align:top"><p>Group</p></td><td><p>Creatinine<br />Clearance<br />(mL/min/1.73m2)</p></td><td style="vertical-align:top"><p>Dosage<br />(mg)</p></td><td style="vertical-align:top"><p>Frequency</p></td></tr></thead><tbody><tr><td><p>Normal</p></td><td><p>&gt; 80</p></td><td><p>1000 to 3000</p></td><td><p>Every 24 hours</p></td></tr><tr><td><p>Mild</p></td><td><p>50 &ndash; 80</p></td><td><p>1000 to 2000</p></td><td><p>Every 24 hours</p></td></tr><tr><td><p>Moderate</p></td><td><p>30 &ndash; 50</p></td><td><p>500 to 1500</p></td><td><p>Every 24 hours</p></td></tr><tr><td><p>Severe</p></td><td><p>&lt; 30</p></td><td><p>500 to 1000</p></td><td><p>Every 24 hours</p></td></tr></tbody></table><p>&nbsp;</p><p>The effect of EFRAM XR on renal impaired patients was not assessed in the controlled study. However, it is expected that the effect on EFRAM XR-treated patients would be similar to the effect seen in controlled studies of immediate-release EFRAM tablets. Clearance of levetiracetam is decreased in patients with renal impairment and is correlated with creatinine clearance [see PHARMACOLOGICAL PROPERTIES (5.2)]<em>.</em>Dose adjustment is recommended for patients with impaired renal function[See&nbsp;DOSAGE and method of administration (4.2)].</p><p>&nbsp;</p><p><em><u>Pediatric Use</u></em></p><p>Safety and effectiveness of EFRAM XR in patients below the age of 16 years have not been established.</p><p><em><u>Geriatric Use</u></em></p><p>There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of EFRAM XR in these patients. It is expected that the safety of EFRAM XR in elderly patients 65 and over would be comparable to the safety observed in clinical studies of immediate-release EFRAM tablets.</p><p>There were 347 subjects in clinical studies of immediate-release levetiracetam that were 65 and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of immediate-release EFRAM in these patients.</p><p>Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function[See PHARMACOLOGICAL PROPERTIES (5.2)].</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Psychiatric Reactions</u></em></strong></p><p><em>EFRAM XR Tablets</em></p><p>In some patients EFRAM XR causes behavioral abnormalities.</p><p>A total of 6.5% of EFRAM XR-treated patients experienced non-psychotic behavioral disorders (reported as irritability and aggression) compared to 0% of placebo-treated patients. Irritability was reported in 6.5% of EFRAM XR-treated patients. Aggression was reported in 1.3% of EFRAM XR-treated patients.</p><p>No patient discontinued treatment or had a dose reduction as a result of these adverse reactions.</p><p>The number of patients exposed to EFRAM XR was considerably smaller than the number of patients exposed to immediate-release EFRAM tablets in controlled trials. Therefore, certain adverse reactions observed in the immediate-release EFRAM controlled trials will likely occur in patients receiving EFRAM XR.</p><p><em>Immediate-Release EFRAM Tablets</em></p><p>A total of 13.3% of adult EFRAM-treated patients compared to 6.2% of placebo patients experienced non-psychotic behavioral symptoms (reported as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional liability, hostility, irritability, and nervousness).</p><p>A total of 1.7% of adult EFRAM-treated patients discontinued treatment due to behavioral adverse events compared to 0.2% of placebo patients. The treatment dose was reduced in 0.8% of adult EFRAM-treated patients and in 0.5% of placebo patients.</p><p>One percent of adult EFRAM-treated patients experienced psychotic symptoms compared to 0.2% of placebo patients.</p><p>Two (0.3%) adult EFRAM-treated patients were hospitalized and their treatment was discontinued due to psychosis. Both events, reported as psychosis, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation.</p><p>The above psychiatric signs and symptoms should be monitored.</p><p><strong><em><u>Suicidal Behavior and Ideation</u></em></strong></p><p>Antiepileptic drugs (AEDs), including EFRAM XR, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p><p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.</p><p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="5"><p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs.</p><p><strong>Table 2: Risk By Indication For Antiepileptic Drugs In The Pooled Analysis</strong></p></td></tr><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Placebo Patients with Events Per 1000 Patients</strong></p></td><td><p><strong>Drug Patients with Events Per 1000 Patients</strong></p></td><td><p><strong>Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</strong></p></td><td><p><strong>Risk Difference: Additional Drug Patients with Events Per 1000 Patients</strong></p></td></tr></thead><tbody><tr><td><p>Epilepsy</p></td><td><p>1.0</p></td><td><p>3.4</p></td><td><p>3.5</p></td><td><p>2.4</p></td></tr><tr><td><p>Psychiatric</p></td><td><p>5.7</p></td><td><p>8.5</p></td><td><p>1.5</p></td><td><p>2.9</p></td></tr><tr><td><p>Other</p></td><td><p>1.0</p></td><td><p>1.8</p></td><td><p>1.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Total</p></td><td><p>2.4</p></td><td><p>4.3</p></td><td><p>1.8</p></td><td><p>1.9</p></td></tr></tbody></table><p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.</p><p>Anyone considering prescribing EFRAM XR or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p><p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p><p><strong><em><u>Somnolence and Fatigue</u></em></strong></p><p><em>EFRAM XR Tablets</em></p><p>In the EFRAM XR double-blind, controlled trial in patients experiencing partial onset seizures, 7.8% of EFRAM XR-treated patients experienced somnolence compared to 2.5% of placebo-treated patients.</p><p>No patient discontinued treatment or had a dose reduction as a result of these adverse reactions.</p><p>The number of patients exposed to EFRAM XR was considerably smaller than the number of patients exposed to immediate-release EFRAM tablets in controlled trials. Therefore, certain adverse reactions observed in the immediate-release EFRAM controlled trials will likely occur in patients receiving EFRAM XR.</p><p><em>Immediate-Release EFRAM Tablets</em></p><p>In controlled trials of adult patients with epilepsy experiencing partial onset seizures, 14.8% of EFRAM-treated patients reported somnolence, compared to 8.4% of placebo patients. There was no clear dose response up to 3000 mg/day. In a study where there was no titration, about 45% of patients receiving 4000 mg/day reported somnolence. The somnolence was considered serious in 0.3% of the treated patients, compared to 0% in the placebo group. About 3% of EFRAM-treated patients discontinued treatment due to somnolence, compared to 0.7% of placebo patients. In 1.4% of treated patients and in 0.9% of placebo patients the dose was reduced, while 0.3% of the treated patients were hospitalized due to somnolence.</p><p>In controlled trials of adult patients with epilepsy experiencing partial onset seizures, 14.7% of EFRAM-treated patients reported asthenia, compared to 9.1% of placebo patients. Treatment was discontinued due to asthenia in 0.8% of treated patients as compared to 0.5% of placebo patients. In 0.5% of treated patients and in 0.2% of placebo patients the dose was reduced due to asthenia.</p><p>Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment.</p><p>Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on EFRAM to gauge whether it adversely affects their ability to drive or operate machinery.</p><p><strong><em><u>Serious Dermatological Reactions</u></em></strong></p><p>Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with levetiracetam. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment. Recurrence of the serious skin reactions following re-challenge with levetiracetam has also been reported. EFRAM XR should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.</p><p><strong><em><u>Coordination Difficulties</u></em></strong></p><p>Coordination difficulties were not observed in the EFRAM XR controlled trial, however, the number of patients exposed to EFRAM XR was considerably smaller than the number of patients exposed to immediate-release EFRAM tablets in controlled trials. However, adverse reactions observed in the immediate-release EFRAM controlled trials may also occur in patients receiving EFRAM XR.</p><p><em>Immediate-Release EFRAM Tablets</em></p><p>A total of 3.4% of adult EFRAM-treated patients experienced coordination difficulties, (reported as either ataxia, abnormal gait, or in coordination) compared to 1.6% of placebo patients. A total of 0.4% of patients in controlled trials discontinued EFRAM treatment due to ataxia, compared to 0% of placebo patients. In 0.7% of treated patients and in 0.2% of placebo patients the dose was reduced due to coordination difficulties, while one of the treated patients was hospitalized due to worsening of pre-existing ataxia. These events occurred most frequently within the first 4 weeks of treatment.</p><p>Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on EFRAM to gauge whether it could adversely affect their ability to drive or operate machinery.</p><p><strong><em><u>Withdrawal Seizures</u></em></strong></p><p>Antiepileptic drugs, including EFRAM XR, should be withdrawn gradually to minimize the potential of increased seizure frequency.</p><p><strong><em><u>Hematologic Abnormalities</u></em></strong></p><p>Although there were no obvious hematologic abnormalities observed in treated patients in the EFRAM XR controlled study, the limited number of patients makes any conclusion tentative. The data from the partial seizure patients in the immediate-release EFRAM controlled studies should be considered to be relevant for EFRAM XR-treated patients.</p><p>In controlled trials of immediate-release EFRAM tablets in patients experiencing partial onset seizures, minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 &times; 106/mm3), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in immediate-release EFRAM-treated patients. A total of 3.2% of treated and 1.8% of placebo patients had at least one possibly significant (&le;2.8 &times; 109/L) decreased WBC, and 2.4% of treated and 1.4% of placebo patients had at least one possibly significant (&le;1.0 &times; 109/L) decreased neutrophil count. Of the treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.</p><p><strong><em><u>Seizure Control During Pregnancy</u></em></strong></p><p>Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No significant pharmacokinetic interactions were observed between levetiracetamor its major metabolite and concomitant medications via human liver cytochrome P450 isoforms, epoxide hydrolase, UDP-glucuronidation enzymes, P-glycoprotein, or renal tubular secretion [see PHARMACOLOGICAL PROPERTIES (5.2)].</p><p>&nbsp;</p><p><em><u>Drug Interactions:</u></em></p><p>In vitro&nbsp;data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above Cmax&nbsp;levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the&nbsp;in vitro&nbsp;glucuronidation of valproic acid.</p><p>Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening with immediate-release EFRAM tablets in the placebo-controlled clinical studies in epilepsy patients. The potential for drug interactions for EFRAM XR is expected to be essentially the same as that with immediate-release EFRAM tablets.</p><p><em>Phenytoin</em></p><p>Immediate-release EFRAM tablets (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin.</p><p><em>Valproate</em></p><p>Immediate-release EFRAM tablets (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion. There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057.</p><p><em>Other Antiepileptic Drugs</em></p><p>Potential drug interactions between immediate-release EFRAM tablets and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.</p><p><em>Oral Contraceptives</em></p><p>Immediate-release EFRAM tablets (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely. Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.</p><p><em>Digoxin</em></p><p>Immediate-release EFRAM tablets (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.</p><p><em>Warfarin</em></p><p>Immediate-release EFRAM tablets (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin. Prothrombin time was not affected by levetiracetam. Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.</p><p><em>Probenecid</em></p><p>Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily. Cssmax&nbsp;of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same. Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057. The effect of immediate-release EFRAM tablets on probenecid was not studied.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Pregnancy</u></em></strong></p><p>Efram XR levels may decrease during pregnancy.</p><p><em><u>Pregnancy Category C</u></em></p><p>There are no adequate and well-controlled studies in pregnant women. In animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therapeutic doses. EFRAM XR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>Oral administration of levetiracetam to female rats throughout pregnancy and lactation led to increased incidences of minor fetal skeletal abnormalities and retarded offspring growth pre- and/or postnatally at doses &ge;350 mg/kg/day (equivalent to the maximum recommended human dose of 3000 mg [MRHD] on a mg/m2&nbsp;basis) and with increased pup mortality and offspring behavioral alterations at a dose of 1800 mg/kg/day (6 times the MRHD on a mg/m2&nbsp;basis). The developmental no effect dose was 70 mg/kg/day (0.2 times the MRHD on a mg/m2&nbsp;basis). There was no overt maternal toxicity at the doses used in this study.</p><p>Oral administration of levetiracetam to pregnant rabbits during the period of organogenesis resulted in increased embryofetal mortality and increased incidences of minor fetal skeletal abnormalities at doses &ge;600 mg/kg/day ( 4 times MRHD on a mg/m2&nbsp;basis) and in decreased fetal weights and increased incidences of fetal malformations at a dose of 1800 mg/kg/day (12 times the MRHD on a mg/m2&nbsp;basis). The developmental no effect dose was 200 mg/kg/day (equivalent to the MRHD on a mg/m2&nbsp;basis). Maternal toxicity was also observed at 1800 mg/kg/day.</p><p>When levetiracetam was administered orally to pregnant rats during the period of organogenesis, fetal weights were decreased and the incidence of fetal skeletal variations was increased at a dose of 3600 mg/kg/day (12 times the MRHD). 1200 mg/kg/day (4 times the MRHD) was a developmental no effect dose. There was no evidence of maternal toxicity in this study.</p><p>Treatment of rats with levetiracetam during the last third of gestation and throughout lactation produced no adverse developmental or maternal effects at oral doses of up to 1800 mg/kg/day (6 times the MRHD on a mg/m2&nbsp;basis).</p><p><strong><em><u>Labor and Delivery</u></em></strong></p><p>The effect of EFRAM XR on labor and delivery in humans is unknown.</p><p><strong><em><u>Nursing Mothers</u></em></strong></p><p>Levetiracetam is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from EFRAM XR, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inform patients that EFRAM XR may cause dizziness and somnolence. Inform patients not to drive or operate machinery until they have gained sufficient experience on EFRAM XR to gauge whether it adversely affects their ability to drive or operate machinery.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are discussed in more details in other sections of labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychiatric Reactions[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicidal Behavior And Ideation[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Somnolence And Fatigue[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious Dermatological Reactions[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coordination Difficulties[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdrawal Seizures[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hematologic Abnormalities[See&nbsp;Special warnings and precautions for use (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizure Control During Pregnancy[See&nbsp;Special warnings and precautions for use (4.4)]</p><p><strong>&nbsp;</strong></p><p><strong><em><u>Clinical Trials Experience</u></em></strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The prescriber should be aware that the adverse reaction incidence figures in the following table, obtained when EFRAM XR was added to concurrent AED therapy, cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical trials. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.</p><p><em><u>EFRAM XRTablets</u></em></p><p>In the controlled clinical study using EFRAM XR in patients with partial onset seizures, the most frequently reported adverse reactions in patients receiving EFRAM XR in combination with other AEDs, for events with rates greater than placebo, were irritability and somnolence.</p><p>Table 3 lists adverse reactions that occurred in at least 5% of epilepsy patients treated with EFRAM XR participating in the placebo-controlled study and were numerically more common than in patients treated with placebo. In this study, either EFRAM XR or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.</p><table border="0" cellspacing="0" cellpadding="0" style="width:60%"><thead><tr><td colspan="3"><p><strong>Table 3: Incidence (%) Of Adverse Reactions In The Placebo-Controlled, Add-On Study By Body System (Adverse Reactions Occurred In At Least 5% Of EFRAM XR-Treated Patients And Occurred More Frequently Than Placebo-Treated Patients)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body System/<br />Adverse Reaction</strong></p></td><td><p><strong>EFRAM XR<br />(N=77)<br />%</strong></p></td><td><p><strong>Placebo<br />(N=79)<br />%</strong></p></td></tr></thead><tbody><tr><td colspan="3"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Nausea</p></td><td><p>5</p></td><td><p>3</p></td></tr><tr><td colspan="3"><p><strong>Infections and Infestations</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Influenza</p></td><td><p>8</p></td><td><p>4</p></td></tr><tr><td><p>&nbsp;&nbsp;Nasopharyngitis</p></td><td><p>7</p></td><td><p>5</p></td></tr><tr><td colspan="3"><p><strong>Nervous System Disorders</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Somnolence</p></td><td><p>8</p></td><td><p>3</p></td></tr><tr><td><p>&nbsp;&nbsp;Dizziness</p></td><td><p>5</p></td><td><p>3</p></td></tr><tr><td colspan="3"><p><strong>Psychiatric Disorders</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Irritability</p></td><td><p>7</p></td><td><p>0</p></td></tr></tbody></table><p><em>Discontinuation or Dose Reduction in the EFRAM XR Controlled Clinical Study</em></p><p>In the controlled clinical study using EFRAM XR, 5.2% of patients receiving EFRAM XR and 2.5% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions that resulted in discontinuation and that occurred more frequently in EFRAM XR-treated patients than in placebo-treated patients were asthenia, epilepsy, mouth ulceration, rash and respiratory failure. Each of these adverse reactions led to discontinuation in a EFRAM XR-treated patient and no placebo-treated patients.</p><p>Table 4 lists the adverse reactions seen in the controlled studies of immediate-release EFRAM tablets in adult patients experiencing partial onset seizures. Although the pattern of adverse reactions in the EFRAM XR study seems somewhat different from that seen in partial onset seizure controlled studies for immediate-release EFRAM tablets, this is possibly due to the much smaller number of patients in this study compared to the immediate-release tablet studies. The adverse reactions for EFRAM XR are expected to be similar to those seen with immediate-release EFRAM tablets.</p><p><em>Immediate-Release EFRAM Tablets</em></p><p>In controlled clinical studies of immediate-release EFRAM tablets as adjunctive therapy to other AEDs in adults with partial onset seizures, the most frequently reported adverse reactions, for events with rates greater than placebo, were somnolence, asthenia, infection and dizziness.</p><p>Table 4 lists adverse reactions that occurred in at least 1% of adult epilepsy patients treated with immediate-release EFRAM tablets participating in placebo-controlled studies and were numerically more common than in patients treated with placebo. In these studies, either immediate-release EFRAM tablets or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.</p><table border="0" cellspacing="0" cellpadding="0" style="width:60%"><thead><tr><td colspan="3"><p><strong>Table 4: Incidence (%) Of Adverse Reactions In Placebo-Controlled, Add-On Studies In Adults Experiencing Partial Onset Seizures By Body System (Adverse Reactions Occurred In At Least 1% Of Immediate-Release EFRAM -Treated Patients And Occurred More Frequently Than Placebo-Treated Patients)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body System/<br />&nbsp;&nbsp;Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Immediate-release EFRAM<br />(N=769)<br />%</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<br />(N=439)<br />%</strong></p></td></tr></thead><tbody><tr><td><p><strong>Body as a Whole</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;&nbsp;Asthenia</p></td><td><p>15</p></td><td><p>9</p></td></tr><tr><td><p>&nbsp;&nbsp;Headache</p></td><td><p>14</p></td><td><p>13</p></td></tr><tr><td><p>&nbsp;&nbsp;Infection</p></td><td><p>13</p></td><td><p>8</p></td></tr><tr><td><p>&nbsp;&nbsp;Pain</p></td><td><p>7</p></td><td><p>6</p></td></tr><tr><td><p><strong>Digestive System</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;&nbsp;Anorexia</p></td><td><p>3</p></td><td><p>2</p></td></tr><tr><td><p><strong>Nervous System</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;&nbsp;Somnolence</p></td><td><p>15</p></td><td><p>8</p></td></tr><tr><td><p>&nbsp;&nbsp;Dizziness</p></td><td><p>9</p></td><td><p>4</p></td></tr><tr><td><p>&nbsp;&nbsp;Depression</p></td><td><p>4</p></td><td><p>2</p></td></tr><tr><td><p>&nbsp;&nbsp;Nervousness</p></td><td><p>4</p></td><td><p>2</p></td></tr><tr><td><p>&nbsp;&nbsp;Ataxia</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Vertigo</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Amnesia</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Anxiety</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Hostility</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Paresthesia</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Emotional Lability</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p><strong>Respiratory System</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;&nbsp;Pharyngitis</p></td><td><p>6</p></td><td><p>4</p></td></tr><tr><td><p>&nbsp;&nbsp;Rhinitis</p></td><td><p>4</p></td><td><p>3</p></td></tr><tr><td><p>&nbsp;&nbsp;Cough Increased</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;Sinusitis</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p><strong>Special Senses</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;&nbsp;Diplopia</p></td><td><p>2</p></td><td><p>1</p></td></tr></tbody></table><p>In addition, the following adverse reactions were seen in other well-controlled studies of immediate-release EFRAM tablets: balance disorder, disturbance in attention, eczema, hyperkinesia, memory impairment, myalgia, personality disorders, pruritus, and vision blurred.</p><p><em>Comparison of Gender, Age and Race</em></p><p>There are insufficient data for EFRAM XR to support a statement regarding the distribution of adverse experience reports by gender, age and race.</p><p><strong><em><u>Postmarketing Experience</u></em></strong></p><p>In addition to the adverse reactions listed above for immediate-release EFRAM tablets, the following adverse events have been identified during post approval use of immediate-release EFRAM tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The listing is alphabetized: abnormal liver function test, agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hepatitis, leukopenia, muscular weakness, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), panic attack, thrombocytopenia, and weight loss. Alopecia has been reported with immediate-release EFRAM use; recovery was observed in majority of cases where immediate-release EFRAM was discontinued.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans</u></em></strong></p><p>The signs and symptoms for EFRAM XR overdose are expected to be similar to those seen with immediate-release EFRAM tablets.</p><p>The highest known dose of oral immediate-release EFRAM received in the clinical development program was 6000 mg/day. Other than drowsiness, there were no adverse reactions in the few known cases of overdose in clinical trials. Cases of somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with immediate-release EFRAM overdoses in postmarketing use.</p><p><strong><em><u>Management of Overdose</u></em></strong></p><p>There is no specific antidote for overdose with EFRAM XR. If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavage; usual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient&#39;s clinical status. A Certified Poison Control Center should be contacted for up to date information on the management of overdose with EFRAM XR.</p><p><strong><em><u>Hemodialysis</u></em></strong></p><p>Standard hemodialysis procedures result in significant clearance of levetiracetam (approximately 50% in 4 hours) and should be considered in cases of overdose. Although hemodialysis has not been performed in the few known cases of overdose, it may be indicated by the patient&#39;s clinical state or in patients with significant renal impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mechanism of action</u></p><p>The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain.</p><p>In vitro&nbsp;and&nbsp;in vivo&nbsp;recordings of epileptiform activity from the hippocampus have shown that levetiracetam inhibits burst firing without affecting normal neuronal excitability, suggesting that levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity.</p><p>Levetiracetam at concentrations of up to 10 &mu;M did not demonstrate binding affinity for a variety of known receptors, such as those associated with benzodiazepines, GABA (gamma-aminobutyric acid), glycine, NMDA (N-methyl-D-aspartate), re-uptake sites, and second messenger systems. Furthermore,&nbsp;in vitro&nbsp;studies have failed to find an effect of levetiracetam on neuronal voltage-gated sodium or T-type calcium currents and levetiracetam does not appear to directly facilitate GABAergic neurotransmission. However,&nbsp;in vitro&nbsp;studies have demonstrated that levetiracetam opposes the activity of negative modulators of GABA- and glycine-gated currents and partially inhibits N-type calcium currents in neuronal cells.</p><p>A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.</p><p>&nbsp;</p><p><u>Pharmacodynamic properties</u></p><p><em><u>Effects on QTc Interval</u></em></p><p>The effects of EFRAM XR on QTc prolongation is expected to be the same as that of immediate-release KEPPRA. The effect of immediate-release EFRAM on QTc prolongation was evaluated in a randomized, double-blind, positive-controlled (moxifloxacin 400 mg) and placebo-controlled crossover study of EFRAM (1000 mg or 5000 mg) in 52 healthy subjects. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 milliseconds. Therefore, there was no evidence of significant QTc prolongation in this study.</p><p><u>Clinical efficacy and safety</u></p><p>The effectiveness of the immediate-release formulation of EFRAM as adjunctive therapy (added to other antiepileptic drugs) in adults was established in three multicenter, randomized, double-blind, placebo controlled clinical studies in 904 patients who had refractory partial onset seizures with or without secondary generalization for at least two years and had taken two or more classical AEDs.</p><p>The effectiveness of EFRAM XR as adjunctive therapy (added to other antiepileptic drugs) was established in one multicenter, randomized, double-blind, placebo-controlled clinical study across 7 countries in patients who had refractory partial onset seizures with or without secondary generalization. Patients enrolled had at least eight partial seizures with or without secondary generalization during the 8-week baseline period and at least two partial seizures in each 4-week interval of the baseline period. Patients were taking a stable dose regimen of at least one and could take a maximum of three AEDs. After a prospective baseline period of 8 weeks, 158 patients were randomized to placebo (N=79) or EFRAM XR (2x500 mg tablets) (N=79) given once daily over a 12-week treatment period.</p><p>The primary efficacy endpoint was the percent reduction over placebo in mean weekly frequency of partial onset seizures. The median percent reduction in weekly partial onset seizure frequency from baseline over the treatment period was 46.1% in the EFRAM XR 1000 mg treatment group (N=74) and 33.4% in the placebo group (N=78). The estimated percent reduction over placebo in weekly partial onset seizure frequency over the treatment period was 14.4% (statistically significant).</p><p>The relationship between the effectiveness of the same daily dose of EFRAM XR and immediate-release EFRAM has not been studied and is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Overview</u></em></p><p>Bioavailability of Efram XR tablets is similar to that of the Efram IR Tablets.&nbsp;The pharmacokinetics (AUC and Cmax) were shown to be dose proportional after single dose administration of 1000 mg, 2000 mg, and 3000 mg extended-release levetiracetam. Plasma half-life of extended-release levetiracetam is approximately 7 hours.</p><p>Levetiracetam is almost completely absorbed after oral administration. The pharmacokinetics of levetiracetam are linear and time-invariant, with low intra- and inter-subject variability. Levetiracetam is not significantly protein-bound (&lt;10% bound) and its volume of distribution is close to the volume of intracellular and extracellular water. Sixty-six percent (66%) of the dose is renally excreted unchanged. The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. It is not liver cytochrome P450 dependent. The metabolites have no known pharmacological activity and are renally excreted. Plasma half-life of levetiracetam across studies is approximately 6-8 hours. The half-life is increased in the elderly (primarily due to impaired renal clearance) and in subjects with renal impairment.</p><p><em><u>Absorption and Distribution</u></em></p><p>Extended-release levetiracetam peak plasma concentrations occur in about 4 hours. The time to peak plasma concentrations is about 3 hours longer with extended-release levetiracetam than with immediate-release tablets.</p><p>Single administration of two 500 mg extended-release levetiracetam tablets once daily produced comparable maximal plasma concentrations and area under the plasma concentration versus time as did the administration of one 500 mg immediate-release tablet twice daily in fasting conditions. After multiple dose extended-release levetiracetam tablets intake, extent of exposure (AUC0-24) was similar to extent of exposure after multiple dose immediate-release tablets intake. Cmax&nbsp;and Cmin&nbsp;were lower by 17% and 26% after multiple dose extended-release levetiracetam tablets intake in comparison to multiple dose immediate-release tablets intake. Intake of a high fat, high calorie breakfast before the administration of extended-release levetiracetam tablets resulted in a higher peak concentration, and longer median time to peak. The median time to peak (Tmax) was 2 hours longer in the fed state.</p><p>Two 750 mg extended-release levetiracetam tablets were bioequivalent to a single administration of three 500 mg extended-release levetiracetam tablets.</p><p><em>Metabolism</em></p><p>Levetiracetam is not extensively metabolized in humans. The major metabolic pathway is the enzymatic hydrolysis of the acetamide group, which produces the carboxylic acid metabolite, ucb L057 (24% of dose) and is not dependent on any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal seizure models. Two minor metabolites were identified as the product of hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-pyrrolidine ring in position 5 (1% of dose). There is no enantiomericinterconversion of levetiracetam or its major metabolite.</p><p><em>Elimination</em></p><p>Levetiracetam plasma half-life in adults is 7 &plusmn; 1 hour and is unaffected by either dose or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance. Levetiracetam clearance is reduced in patients with impaired renal function[See&nbsp;Use in Specific Populations in&nbsp;Dosage and method of Administration (4.2)].</p><p>&nbsp;</p><p><em>Special Populations</em></p><p><em>Elderly</em></p><p>There are insufficient pharmacokinetic data to specifically address the use of extended-release levetiracetam in the elderly population.</p><p>Pharmacokinetics of immediate-release levetiracetam were evaluated in 16 elderly subjects (age 61-88 years) with creatinine clearance ranging from 30 to 74 mL/min. Following oral administration of twice-daily dosing for 10 days, total body clearance decreased by 38% and the half-life was 2.5 hours longer in the elderly compared to healthy adults. This is most likely due to the decrease in renal function in these subjects.</p><p><em>Pediatric Patients</em></p><p>Safety and effectiveness of EFRAM XR in patients below the age of 16 years have not been established.</p><p><em>Pregnancy</em></p><p>EFRAM XR levels may decrease during pregnancy.</p><p><em>Gender</em></p><p>Extended-release levetiracetam Cmax&nbsp;was 21-30% higher and AUC was 8-18% higher in women (N=12) compared to men (N=12). However, clearances adjusted for body weight were comparable.</p><p><em>&nbsp;</em></p><p><em>Race</em></p><p>Formal pharmacokinetic studies of the effects of race have not been conducted with extended-release or immediate-release levetiracetam. Cross study comparisons involving Caucasians (N=12) and Asians (N=12), however, show that pharmacokinetics of immediate-release levetiracetam were comparable between the two races. Because levetiracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected.</p><p><em>Renal Impairment</em></p><p>The effect of EFRAM XR on renally impaired patients was not assessed in the controlled study. However, it is expected that the effect on EFRAM XR-treated patients would be similar to that seen in controlled studies of immediate-release EFRAM tablets. In patients with end stage renal disease on dialysis, it is recommended that immediate-release EFRAM be used instead of EFRAM XR.</p><p>The disposition of immediate-release levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group (CLcr = 50-80 mL/min), 50% in the moderate group (CLcr = 30-50 mL/min) and 60% in the severe renal impairment group (CLcr&lt;30 mL/min). Clearance of levetiracetam is correlated with creatinine clearance.</p><p>In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects (CLcr&gt;80mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4- hour hemodialysis procedure.</p><p>Dosage should be reduced in patients with impaired renal function receiving levetiracetam; immediate-release levetiracetam should be given to patients on dialysis [SeeDOSAGE and method of administration(4.2)].</p><p><em>Hepatic Impairment</em></p><p>In subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of levetiracetam were unchanged. In patients with severe hepatic impairment (Child-Pugh C), total body clearance was 50% that of normal subjects, but decreased renal clearance accounted for most of the decrease. No dose adjustment is needed for patients with hepatic impairment.</p><p><em><u>Drug Interactions:</u></em></p><p>In vitro&nbsp;data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above Cmax&nbsp;levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the&nbsp;in vitro&nbsp;glucuronidation of valproic acid.</p><p>Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening with immediate-release EFRAM tablets in the placebo-controlled clinical studies in epilepsy patients. The potential for drug interactions for EFRAM XR is expected to be essentially the same as that with immediate-release EFRAM tablets.</p><p><em>Phenytoin</em></p><p>Immediate-release EFRAM tablets (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin.</p><p><em>Valproate</em></p><p>Immediate-release EFRAM tablets (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion. There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057.</p><p><em>Other Antiepileptic Drugs</em></p><p>Potential drug interactions between immediate-release EFRAM tablets and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.</p><p><em>Oral Contraceptives</em></p><p>Immediate-release EFRAM tablets (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely. Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.</p><p><em>Digoxin</em></p><p>Immediate-release EFRAM tablets (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.</p><p><em>Warfarin</em></p><p>Immediate-release EFRAM tablets (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin. Prothrombin time was not affected by levetiracetam. Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.</p><p><em>Probenecid</em></p><p>Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily. Cssmax&nbsp;of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same. Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057. The effect of immediate-release EFRAM tablets on probenecid was not studied</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The prescriber should be aware that the adverse reaction incidence figures in the following table, obtained when EFRAM XR was added to concurrent AED therapy, cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical trials. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.</p><p><em><u>EFRAM XR Tablets</u></em></p><p>In the controlled clinical study using EFRAM XR in patients with partial onset seizures, the most frequently reported adverse reactions in patients receiving EFRAM XRin combination with other AEDs, for events with rates greater than placebo, were irritability and somnolence.</p><p>Table 3 lists adverse reactions that occurred in at least 5% of epilepsy patients treated with EFRAM XR participating in the placebo-controlled study and were numerically more common than in patients treated with placebo. In this study, either EFRAM XR or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.</p><table border="0" cellspacing="0" cellpadding="0" style="width:60%"><thead><tr><td colspan="3"><p><strong>Table 3: Incidence (%) Of Adverse Reactions In The Placebo-Controlled, Add-On Study By Body System (Adverse Reactions Occurred In At Least 5% Of EFRAM XR-Treated Patients And Occurred More Frequently Than Placebo-Treated Patients)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body System/<br />Adverse Reaction</strong></p></td><td><p><strong>EFRAM XR<br />(N=77)<br />%</strong></p></td><td><p><strong>Placebo<br />(N=79)<br />%</strong></p></td></tr></thead><tbody><tr><td colspan="3"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Nausea</p></td><td><p>5</p></td><td><p>3</p></td></tr><tr><td colspan="3"><p><strong>Infections and Infestations</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Influenza</p></td><td><p>8</p></td><td><p>4</p></td></tr><tr><td><p>&nbsp;&nbsp;Nasopharyngitis</p></td><td><p>7</p></td><td><p>5</p></td></tr><tr><td colspan="3"><p><strong>Nervous System Disorders</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Somnolence</p></td><td><p>8</p></td><td><p>3</p></td></tr><tr><td><p>&nbsp;&nbsp;Dizziness</p></td><td><p>5</p></td><td><p>3</p></td></tr><tr><td colspan="3"><p><strong>Psychiatric Disorders</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;Irritability</p></td><td><p>7</p></td><td><p>0</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>For Efram XR 500 mg</u></em></p><p><em><u>&nbsp;</u></em></p><table border="0" cellspacing="0" cellpadding="0" style="width:499px"><tbody><tr><td style="vertical-align:top"><p><strong>Excipients</strong></p><p>Avicel pH 101: 12.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Povidone 30: 13.333 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water: qs.</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl methylcellulose K15M: 210.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Colloidal silicon dioxide: 3.667 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc: 3.667 mg.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Coating composition</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl methylcellulose: 9.750 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Titanium dioxide pharma grade: 3.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene glycol MW6000: 1.500 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc: 0.750 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water: qs</p></td></tr></tbody></table><p><em><u>For Efram XR 750 mg</u></em></p><p><em><u>&nbsp;</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:499px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Excipients</strong></p></td></tr><tr><td style="vertical-align:top"><p>Avicel pH 101</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>18.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Povidone 30</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>qs</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl methylcellulose K15M</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>315.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Colloidal silicon dioxide</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>5.500 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>5.500 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>11.000 mg.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Coating composition</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl methylcellulose</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>14.625 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Titanium dioxide pharma grade</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>4.500 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene glycol MW6000</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2.250 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.125 mg.</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>qs</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do no store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30/pack</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reel OPA/AL /PVC blister and aluminum foil</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DAMMAM PHARMA
Dammam Pharmaceutical plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                            March 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>